Achaogen Gets ₤4.1M Grant From Wellcome Trust

San Francisco-based Achaogen, which is developing biopharmaceuticals for treating multi-drug resistant bacterial infections, said Thursday that the firm has received £4.1 million from the Wellcome Trust, to help the firm's studies. According to the firm, the Seeding Drug Discovery award will go to enable studies and advancement into clinical trials of Achaogenís portfolio of proprietary neoglycosides for the treatment of Gram-negative bacterial infections. Achaogen is venture backed by 5 AM Ventures, ARCH Venture Partners and Domain Associates, Venrock Associates and Versant Ventures.